Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.42 |
| ▸ | ABL1 | P00519 | 5/20 | 0.42 |
| ▸ | INSR | P06213 | 5/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.42 |
| ▸ | CDK2 | P24941 | 5/20 | 0.42 |
| ▸ | PLK1 | P53350 | 5/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952629 | 0.90 | EGFR (0.53) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL2943738 | 0.89 | EGFR (0.46) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL2255723 | 0.87 | EGFR (0.47) | EGFRGAKERBB2ERBB3ERBB4 | |
| SCHEMBL6103497 | 0.87 | NOS3 (0.44) | EGFR | |
| SCHEMBL2950338 | 0.87 | EGFR (0.46) | EGFRGAKERBB2ABL1INSR | |
| SCHEMBL2941237 | 0.86 | EGFR (0.46) | EGFRGAKERBB2ABL1INSR | |
| SCHEMBL141513 | 0.86 | EGFR (0.44) | EGFRGAKERBB2ABL1INSR | |
| SCHEMBL2250951 | 0.83 | EGFR (0.50) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL2249953 | 0.83 | SYK (0.44) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL6485238 | 0.82 | EGFR (0.47) | EGFRGAKERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| EP-2045245-B1 | INREVERSIBLE PROTEIN TYROSINE KINASES INHIBITORS AND THE PREPARATION METHODS AND USES THEREOF | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2013-10-23 | — | — | EP | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-7754729-B2 | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-07-13 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
| EP-2045245-A1 | INREVERSIBLE PROTEIN TYROSINE KINASES INHIBITORS AND THE PREPARATION METHODS AND USES THEREOF | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | ABL1, MAP3K7, MAP3K5 | EGFR 616/4885GAK 114/4885ERBB2 199/4885 |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885GAK 390/4885ERBB2 170/4885 |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885GAK 390/4885ERBB2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.